Health Care Activity
Hims eyes growth in its weight loss business, despite end of semaglutide shortage
semaglutide, weight loss business, United States Food and Drug Administration, Growth, Hims
AI-Guided Cardiac Ablation Outperforms Standard Treatment for Persistent Atrial Fibrillation
Volta Medical, artificial intelligence, cardiac ablation, atrial fibrillation, TAILORED-AF trial, pulmonary vein isolation, electrophysiology
FDA Issues Import Alerts for Two Chinese API Manufacturers Following Failed Inspections
FDA, import alert, Chinese API manufacturers, failed inspections, quality control, Wuhu Nuowei Chemistry, Chengdu Innovation Pharmaceutical
Hims & Hers Super Bowl Ad Sparks Controversy Over Weight Loss Drug Marketing
Hims & Hers, Super Bowl ad, weight loss drugs, FDA scrutiny, compounded GLP-1 drugs, pharmaceutical advertising, telehealth, consumer safety
Pliant Therapeutics Halts Key Fibrosis Drug Trial, Stock Plummets Amid Uncertainty
Pliant Therapeutics, bexotegrast, idiopathic pulmonary fibrosis, BEACON-IPF trial, clinical trial pause, stock crash, Data Safety Monitoring Board
Eli Lilly’s Zepbound Surpasses $4.9 Billion in First Year Sales Despite Q4 Shortfall
Eli Lilly, Zepbound, obesity drug, Q4 2024 earnings, pharmaceutical revenue, GLP-1 medications, Mounjaro, 2025 guidance
AstraZeneca Shares Rise as China Investigation Impact Appears Limited
AstraZeneca, China investigation, share price, financial performance, import taxes, investor confidence
LinusBio Introduces ClearStrand-ASD: Revolutionary Autism Diagnostic Aid Using Hair Analysis
LinusBio, ClearStrand-ASD, autism diagnostic, hair analysis, biomarker test, early detection, negative predictive value, exposome medicine
U.S. Hospitals Urge Trump to Exempt Medical Supplies and Pharmaceuticals from New Tariffs
Tariffs, medical supplies, pharmaceuticals, American Hospital Association, China, Mexico, Canada, healthcare costs, supply chain disruption, patient safety
Pfizer Exceeds Q4 Expectations: COVID-19 Products and Cost-Cutting Drive Strong Performance
Pfizer, Q4 earnings, COVID-19 portfolio, cost-cutting initiatives, revenue growth, Paxlovid, financial recovery, 2025 guidance